India is seeing a new surge in COVID-19 cases, with active cases reaching over 3,395 as of May 31 — nearly three times the number in a little over two weeks. Kerala, Maharashtra, and Delhi have turned into the biggest hotspots, even though health authorities continue to insist that severity is low. The increase, while not alarming in terms of hospitalizations, has seen India's health authorities keeping a closer watch with the identification of new Omicron subvariants and local clusters of cases.

With a sharp spike in active cases India is back on the global health radar. Though the numbers are still low compared to earlier waves, the rising trend in a number of states, along with the identification of new Omicron subvariants, is worth examining.

Also Read: Colon Cancer Is Rising In Millennials- But This One Symptom Still Feels Too Embarrassing To Talk About

India has witnessed an increase in active COVID-19 cases threefold in the last two weeks, from 1,010 on May 19 to 3,395 on May 31, with official government data. The rise is specifically prominent in Kerala, Maharashtra, and Delhi — regions that have typically been early warning signs of wider transmission trends within the country.

Kerala, which currently holds the highest number of active cases at 1,336, has seen a surge from just 430 cases reported on May 26. Maharashtra follows closely with 467 active cases, more than doubling from its 209 count just days ago. Delhi’s trajectory is also concerning, with a leap from 105 to 375 cases in the same period.

Although these figures are still small compared to the peak of the pandemic, the week-on-week surge suggests a possible first wave of transmission that is being watched closely by experts.

Also Read: Type 2 Diabetes And High Blood Pressure Now Affect 1 In 8 Americans, Study Links Combo To Early Death Risk

Covid Cases: The Current Clinical Scenario

As much as there has been an increase in case numbers, the severity of infection is still low, highlight the Indian health officials and experts. Majority of the patients are recovering under home isolation and only a few need hospitalization.

Official sources and the Indian Council of Medical Research (ICMR) indicated that there is "no cause for concern" in terms of public health emergency. ICMR Director General Dr. Rajiv Bahl provided assurances to the public, saying, "As of now, the severity is generally low. There's nothing to worry about. We should be vigilant and always be prepared."

This indicates that even as the rate of transmission could be increasing, the healthcare system is not getting strained, and the virus remains following a clinically milder pattern than in earlier waves.

Also Read: How “Safe” Vaping Is Hooking A New Generation On Nicotine?

Where Covid Cases Are Rising?

India's new COVID-19 scenario is extremely regionalized, with southern and western states witnessing initial hints of flare-ups prior to infections starting to rise in northern India.

Here's a closer examination of major states:

Kerala: From 430 cases on May 26 to 1,336 on May 31. Six fatalities have been reported.

Maharashtra: Cases went from 209 to 467; seven deaths have been reported.

Delhi: Triplication of cases, from 105 to 375, with three deaths.

Karnataka: From 47 to 234 active cases in under a week.

Tamil Nadu, Gujarat, Uttar Pradesh, West Bengal, Rajasthan, Madhya Pradesh, and Punjab have all experienced moderate increases.

These figures do not only reflect an increase in transmission but a geographical spread that crosses urban and semi-urban hubs, increasing the stakes for surveillance and containment.

Four COVID deaths in India in the past 24 hours — one in each of Delhi, Kerala, Karnataka, and Uttar Pradesh. Although deaths are still in single digits, the number of deaths in this new spike includes:

• Kerala (6 deaths since May 26)
• Maharashtra (7 deaths)
• Karnataka and Delhi (3 deaths each)
• Other states like Tamil Nadu, Gujarat, Rajasthan, Madhya Pradesh, and Punjab (1 death each)

With the present low rates of hospitalization and minimal clinical severity, these deaths are being assessed in the context of co-morbidities and age-related susceptibility.

Is Multi-Variant Spread Behind the Covid Surge In India?

Epidemiologists are particularly interested in understanding whether new variants may be fueling this latest uptick. According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), two new Omicron subvariants have been detected in India:

NB.1.8.1: Detected in Tamil Nadu in April

LF.7: Four cases detected in Gujarat in May

Globally, these variants have contributed to a rise in infections in Southeast Asian countries like Singapore, Hong Kong, and parts of China.

Still, the World Health Organization (WHO) now categorizes both NB.1.8.1 and LF.7 as "variants under monitoring" rather than "variants of concern" or "variants of interest." The WHO's current position is that:

"Based on the evidence available, the added public health risk from NB.1.8.1 is assessed as low at a global level."

The most common circulating strain in India is JN.1, with 53% of the sequenced cases, followed by BA.2 with 26%, while the rest of the 20% consists of other Omicron sublineages.

Covid-19: Surveillance and Public Health Strategy

India's response to the ongoing surge is being organized through the Integrated Disease Surveillance Programme (IDSP). The government is focusing on genomic sequencing, local containment strategies, and respiratory hygiene awareness.

Public health messaging remains on high alert but against panic. No restrictions on travel, lockdowns, or new public orders have been implemented thus far.

Dr. Bahl once again reinforced, "People do not need to take any immediate action. They should follow normal precautions. So, there is nothing special to do right now."

That means maintaining current best practices like handwashing, mask-wearing in close indoor environments, and self-isolation when symptomatic.

Covid-19: Should the World Be Concerned Now?

For the global community, India's recent development is a reminder of the unpredictable nature of the pandemic. Although the world has largely left behind COVID-19 as an emergency, localized outbreaks in densely populated areas like India can ripple outward — particularly if emerging variants start to demonstrate greater transmissibility or immune escape.

The positive news still is that vaccines continue to provide strong protection against severe illness, and India's national immunization program has maintained high coverage in adult groups. However, ongoing genomic surveillance and real-time data transparency will remain crucial to avert larger outbreaks.

India's COVID-19 surge, while of limited magnitude and clinical severity, is a multifaceted convergence of regional patterns of transmission, emerging variant sequences, and preparedness in public health. With cases being largely mild and mortality rates low, the nation's health care system is still in hand but not resting on its laurels.

In the meantime, there is no cause for global alarm. Nevertheless, India's experience should prompt health systems everywhere to remain on high alert, keep genomic surveillance going, and inform the public in a transparent manner. The virus is evolving, but so is our combined ability to deal with it.

In a growing food safety alert, the U.S. Food and Drug Administration (FDA) has escalated a butter recall to a Class II risk level following concerns over undeclared allergens. The product in question, European Style Butter Blend manufactured by Bunge North America Inc., was found to contain milk that was not listed on the packaging label.

Class II Recall Indicates Moderate Health Risk

The risk reclassification, issued on Wednesday, July 30, places the product under the FDA’s second-highest warning level. According to the FDA, a Class II recall involves “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

While no illnesses or allergic reactions have been reported so far, the undeclared presence of milk poses a potential health hazard to people with dairy allergies or lactose intolerance.

Initial Voluntary Recall Announced in Mid-July

The recall began as a voluntary measure by Bunge on July 14, when the company announced it was pulling approximately 64,800 pounds, or 1,800 cases, of its one-pound butter blocks from shelves. The recalled butter was packed in white paperboard cases, each containing 36 one-pound blocks.

The affected products carry the lot code 5064036503 and were shipped to 12 distribution centers across the United States and one in the Dominican Republic.

Why the Undeclared Milk Is a Serious Concern

Milk is one of the nine major food allergens identified by the FDA, alongside eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. The FDA mandates clear labeling of such allergens because exposure, even in small amounts, can cause a range of reactions, from mild discomfort to life-threatening symptoms.

Food-related allergic reactions may include hives, facial swelling, vomiting, coughing, and skin irritation. More severe responses can result in anaphylaxis, a rapid-onset, whole-body allergic reaction that may lead to shock and, in extreme cases, death.

According to the Mayo Clinic, anaphylaxis occurs when the immune system floods the body with chemicals in response to an allergen. This can cause a sudden drop in blood pressure, narrowing of the airways, and potential organ failure if not treated immediately.

FDA Reiterates Importance of Allergen Labeling

In light of the recall, the FDA has emphasized the importance of allergen labeling and said it continues to enforce regulations requiring companies to clearly list all ingredients and potential allergens on packaging.

“More specific labeling requirements exist for foods that can cause allergies or other hypersensitivity reactions,” the agency stated. “These rules are designed to prevent accidental consumption of allergens and to protect consumers with dietary restrictions.”

The FDA also advised that anyone who experiences symptoms of an allergic reaction after consuming the recalled butter should “stop eating the food immediately, evaluate the need to use emergency medication (such as epinephrine), and seek medical attention.”

Company Yet to Comment

As of August 2, Bunge North America has not issued an updated public statement in response to the FDA’s reclassification and did not respond to a request for comment.

Food Safety Under Scrutiny Amid Other Recent Recalls

This butter recall follows a string of other high-profile food safety incidents this year. In recent weeks, more than 110,000 cases of popular chocolate ice cream bars were recalled across 23 states. Target-branded baby food was also pulled from shelves for containing “elevated levels of lead.”

Not forever, but what if you could press pause on Alzheimer’s just long enough to enjoy a few more good years? That is the tantalising promise behind a new drug called lecanemab, hailed as a game-changer in the fight against dementia.

The drug has already been licensed for use in the UK after trials showed it could slow the pace of decline in people with early-stage Alzheimer’s. But new long-term findings are turning cautious hope into something stronger: patients who stayed on lecanemab for four years experienced a noticeable delay in the disease's progression. Some even showed no decline at all.

How It Works

In the initial 18-month trial, the drug delayed Alzheimer’s progression by just under six months. That might not sound like much, but it’s the long game that matters here. Among 478 patients who remained on the drug for four years, the average delay before their disease advanced to the next stage stretched to almost 11 months.

Even more striking: 69 per cent of those with low levels of tau saw no decline at all over the four years. And over half in that same group actually improved their cognitive scores.

A Slow Slide Instead of a Steep Drop

Typically, people with mild Alzheimer’s see their scores on memory and function tests worsen by one or two points each year. But for those taking lecanemab, the total decline across four years was just 1.75 points. That’s a major shift in the rhythm of the disease, changing it from a downhill tumble to a slow shuffle.

Professor Christopher Van Dyck, who led the study at Yale School of Medicine, puts it simply: “You will get worse over time, but it will take longer to get there.” That extra time could mean more independence, more connection with loved ones, and more living.

Why Early Treatment is Key

This makes a strong case for early diagnosis and intervention, which could shift the way we approach Alzheimer’s care. No longer is it just about managing symptoms; it’s about changing the trajectory of the disease.

Not a Cure, But a Clear Step Forward

Lecanemab isn’t a miracle cure. It doesn’t reverse Alzheimer’s, and it’s not suitable for all patients. But experts say it’s a major milestone. Reportedly, this is the first wave of disease-modifying treatments and there’s still plenty to understand.

Other Contenders in the Ring

Lecanemab isn’t the only drug showing promise. A similar treatment called donanemab was tested over a three-year period, though it was only administered for 18 months. Still, the results were encouraging: patients on the drug gained an extra six to 12 months before their disease progressed.

That might not sound earth-shattering, but in a condition where time is everything, even a few more months of clarity and connection can be priceless.

The research is still evolving, but the signs are encouraging. With continued trials, this could be the start of a new chapter in dementia treatment, one where patients and families have more time to prepare, more time to enjoy life, and more hope than ever before.

When 63-year-old John Starns slumped on a train station bench in Sevenoaks, drenched in sweat and struggling to stay upright, most passers-by assumed he was drunk. He looked wobbly, pale, and visibly disoriented. But what looked like an awkward case of public intoxication turned out to be something far more sinister: a brain tumour hiding behind symptoms commonly mistaken for vertigo.

From “It’s Just Vertigo” to “You Have a Brain Tumour”

Three months and one MRI scan later, John finally got the truth. He reportedly had a vestibular schwannoma, a rare, benign brain tumour sitting on the nerve that connects the brain to the inner ear. It was affecting his balance, hearing, and overall coordination, symptoms that, in hindsight, were never typical of garden-variety vertigo.

What is Vestibular Schwannoma?

That is why the symptoms can masquerade as something much less serious.

• Dizziness or vertigo
• Hearing loss in one ear
• Ringing or buzzing sounds (tinnitus)
• Poor sound localisation
• In more advanced cases, numbness on one side of the face

Because these tumours grow at a glacial pace, symptoms tend to hide for months or even years. According to Cancer Research UK, they account for around 8 per cent of all brain tumours, with risk increasing significantly after the age of 65. In rare cases, they are linked to a genetic condition called neurofibromatosis, which often causes tumours on both sides of the brain.

Why Dizziness Deserves a Second Look

For John, it was not just one woozy episode. It was a string of unsettling, spin-the-room moments that left him lying flat on his back, eyes squeezed shut, praying for the world to stop pirouetting. And while vertigo was the first suspect, his brain had other plans, like growing a tumour on his vestibulocochlear nerve.

That is the thing with dizziness: it is vague, common, and often misunderstood. It can signal anything from low blood pressure and ear infections to neurological conditions that need serious medical attention. But because it is so easy to dismiss and hard to describe without wildly gesturing, it often gets brushed under the rug until it insists on being noticed.

If you face dizziness, do not ignore it. Especially if the dizziness is intense, recurrent, or comes with sidekicks like hearing loss, balance issues, or ringing in your ears.